Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Cologne |
---|---|
Information provided by: | University of Cologne |
ClinicalTrials.gov Identifier: | NCT00346684 |
First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab
Condition | Intervention | Phase |
---|---|---|
Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD) |
Drug: Rituximab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Rituximab in Primary LPHD (RIPL) - First Line Therapy for Patients With Lymphocyte Predominant Hodgkin´s Disease (LPHD) in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab. |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | RIPL |
Study First Received: | June 29, 2006 |
Last Updated: | August 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00346684 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Lymphoma LPHD Rituximab |
Lymphatic Diseases Antibodies Hodgkin's disease Immunoproliferative Disorders Rituximab |
Hodgkin lymphoma, adult Lymphoproliferative Disorders Hodgkin Disease Lymphoma Immunoglobulins |
Neoplasms Neoplasms by Histologic Type Immunologic Factors Immune System Diseases Antineoplastic Agents |
Therapeutic Uses Physiological Effects of Drugs Antirheumatic Agents Pharmacologic Actions |